Other Issues

Rather than legislate additional state-level extended producer responsibility mandates aimed at packaging, lawmakers should support manufacturers already innovating sustainability solutions within the FDA's extensive regulatory framework that balances both environmental considerations and patient safety needs.

This page serves as a central resource for the latest updates on tariffs and trade policy announcements from the White House that may impact our industry. Below is timely information including official statements and guidance for members, media, and other stakeholders navigating changes in trade and supply chain policy. We are committed to keeping you informed and engaged as we advocate for access, affordability, and innovation.

Lawmakers should support the centralized progress made on ingredient evaluation, labeling, and packaging protections by specialized national children’s health agencies instead of allowing jurisdiction confusion that ultimately hinders healthcare advancement for all ages.

FDA Announcement of a proposed safety-based Administrative Order that proposes to add a skin allergy warning to labeling requirements for acetaminophen-containing drug products.

The bipartisan federal Combat Meth Epidemic Act strikes the proper policy balance between restricting pseudoephedrine access for illicit use without unduly burdening consumers seeking safe, effective cold relief. Therefore, state legislators should refrain from overriding federal guidelines requiring prescriptions for these legitimate over-the-counter medications.

CHPA supports the Pharmaceutical Cargo Security Coalition, an organization dedicated to preventing cargo theft in pharmaceutical logistics operations.

The Standardized Information on Dietary Ingredients (SIDI) Work Group has released three voluntary guidelines, intended to help the dietary supplement industry comply with cGMP regulations.